Cardiovascular and renal outcomes of sodium–glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes post-PCI: a meta-analysis of 14,511 patients
SGLT-2i demonstrates more clinical benefits, and current evidence supports its initiation over DPP-4i in T2DM patients after PCI.
Authors
- A Badran (ORCID: https://orcid.org/0009-0002-8445-778X)
- Mahmoud Balata (ORCID: https://orcid.org/0000-0003-4744-1703)
- Mohamed Ibrahim Gbreel (ORCID: https://orcid.org/0000-0002-4030-942X)
- Abdelrahman M. Tawfik
Institutions
- Ain Shams University (EG)
- October 6 University (EG)
- University of Rostock (DE)
- Alexandria University (EG)
Publication Details
- Journal
- Diabetology & Metabolic Syndrome
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1186/s13098-025-02080-1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00